Twenty-six years of enteric fever in Australia: An epidemiological analysis of antibiotic resistance

Medical Journal of Australia

Volumn 196, Issue 5, 2012, Pages 332-336

  Commons, Robert J ^a   McBryde, Emma ^a   Valcanis, Mary ^b   Powling, Joan ^b   Street, Alan ^a   Hogg, Geoff ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; NALIDIXIC ACID; TRIMETHOPRIM;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; BACTERIUM ISOLATION; BANGLADESH; CAMBODIA; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; INDIA; INDONESIA; INFANT; LEBANON; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANCE; MYANMAR; NEPAL; PAKISTAN; PAPUA NEW GUINEA; PARATYPHOID FEVER; PHILIPPINES; RETROSPECTIVE STUDY; SALMONELLA PARATYPHI; SALMONELLA TYPHI; SOUTHEAST ASIA; SRI LANKA; THAILAND; TYPHOID FEVER; VIET NAM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASIA, SOUTHEASTERN; AUSTRALIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LOGISTIC MODELS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NALIDIXIC ACID; RETROSPECTIVE STUDIES; SALMONELLA TYPHI; TYPHOID FEVER; YOUNG ADULT;

EID: 84859152008     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.10082     Document Type: Article

References (25)

1. Crump J A, Luby S P, Mintz E D. The global burden of typhoid fever. Bull World Health Organ 2004; 82: 346-353.
2. Parry C M. Typhoid fever. Curr Infect Dis Rep 2004; 6: 27-33.
3. Anand A C, Kataria V K, Singh W, et al. Epidemic multiresistant enteric fever in eastern India. Lancet 1990; 335: 352.
4. Antibiotic expert group. Therapeutic guidelines: antibiotic. Version 14. Melbourne: Therapeutic Guidelines Limited, 2010.
5. Hume S, Schulz T, Vinton P, et al. Increasing rates and clinical consequences of nalidixic acidresistant isolates causing enteric fever in returned travellers: an 18-year experience. Eur J Clin Microbiol Infect Dis 2009; 28: 963-970.
6. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard - eighth edition. Wayne, Pa: CLSI, 2009. (CLSI document M07-A8.)
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement. Wayne, Pa: CLSI, 2011. (CLSI document M100-S21.)
8. Rowe B, Ward L R, Threlfall EJ. Multidrug-resistant Salmonella Typhi: a worldwide epidemic. Clin Infect Dis 1997; 24: S106-S109.
9. Crump J A, Kretsinger K, Gay K, et al. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study. Antimicrob Agents Chemother 2008; 52: 1278-1284.
10. Australian Bureau of Statistics. Australian historical population statistics, 2008. http:// www.abs.gov.au/AUSSTATS/abs@.nsf/ DetailsPage/3105.0.65.0012008?. Open Document (accessed Nov 2011).
11. Centers for Disease Control and Prevention (CDC). Notifiable diseases and mortality tables. MMWR Morb Mortal Wkly Rep 2010; 59: 168-181.
12. United Kingdom Health Protection Agency. Salmonella by serotype. 2011. http://www.hpa.org.uk/Topics/InfectiousDiseases/ InfectionsAZ/Salmonella/EpidemiologicalData/ salmDataHuman (accessed Oct 2011).
13. Demczuk W H, Finley R, Nadon C, et al. Characterization of antimicrobial resistance, molecular and phage types of Salmonella enterica serovar Typhi isolations. Epidemiol Infect 2010; 138: 1414-1426.
14. Chitnis S, Chitnis V, Hemvani N, et al. Ciprofloxacin therapy for typhoid fever needs reconsideration. J Infect Chemother 2006; 12:402-404.
15. Rahman M M, Haq J A, Morshed MA, et al. Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin-an emerging problem in Bangladesh. Int J Antimicrob Agents 2005; 25: 345-346.
16. Shirakawa T, Acharya B, Kinoshita S, et al. Decreased susceptibility to fluoroquinolones and gyrA gene mutation in the Salmonella enteric serovar Typhi and Paratyphi A isolated in Katmandu, Nepal, in 2003. Diagn Microbiol Infect Dis 2006; 54: 299-303.
17. Kasper M R, Sokhal B, Blair P J, et al. Emergence of multidrug-resistant Salmonella enterica serovar Typhi with reduced susceptibility to fluoroquinolones in Cambodia. Diagn Microbiol Infect Dis 2010; 66: 207-209.
18. Hatta M, Ratnawati. Enteric fever in endemic areas of Indonesia: an increasing problem of resistance. J Infect Dev Ctries 2008; 2: 279-282.
19. Lynch M F, Blanton E M, Bulens S, et al. Typhoid fever in the United States, 1999-2006. JAMA 2009; 302: 859-865.
20. Threlfall E J, de Pinna E, Day M, et al. Alternatives to ciprofloxacin use for enteric fever, United Kingdom. Emerg Infect Dis 2008; 14: 860-861.
21. Parry C M, Vinh H, Chinh NT, et al. The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy. PLoS Negl Trop Dis 2011; 5: e1163.
22. Molloy A, Nair S, Cooke F J, et al. First report of Salmonella enterica serotype Paratyphi A azithromycin resistance leading to treatment failure. J Clin Microbiol 2010; 48: 4655-4657.
23. Park-Wyllie L Y, Juurlink D N, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354:1352-1361.
24. Angell S Y, Cetron M S. Health disparities among travellers visiting friends and relatives abroad. Ann Intern Med 2005; 142: 67-72.
25. Nguyen T Q, Reddy V, Sahl S, et al. Importance of travel in domestically acquired typhoid fever infections: opportunities for prevention and early detection. J Immigr Minor Health 2009; 11:139-142.